Basic mechanisms of kynurenine actions in the central nervous system

Advances in Experimental Medicine and Biology

Volumn 398, Issue , 1996, Pages 195-201

  Stone, T W ^a   MacGregor, D G ^a   Smith, R A ^a   Jones, P ^a   Behan, W M H ^a   Graham, D I ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; DRUG DERIVATIVE; INDOL 3 YL PYRUVIC ACID; INDOL-3-YL PYRUVIC ACID; INDOLE DERIVATIVE; KYNURENIC ACID; KYNURENINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROPROTECTIVE AGENT; QUINOLINIC ACID;

ANIMAL; CENTRAL NERVOUS SYSTEM; DRUG EFFECT; HUMAN; MAMMAL; METABOLISM; NERVE CELL; PHYSIOLOGY; REVIEW;

ANIMALS; ANTICONVULSANTS; CENTRAL NERVOUS SYSTEM; HUMANS; INDOLES; KYNURENIC ACID; KYNURENINE; MAMMALS; NEURONS; NEUROPROTECTIVE AGENTS; QUINOLINIC ACID; RECEPTORS, N-METHYL-D-ASPARTATE;

EID: 0030341683     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4613-0381-7_32     Document Type: Article

References (37)

1. Beal, M.F., Ferrante, R.J., Swartz, K.J. and Kowall, N.W., 1991, Chronic quinolinic acid lesions in rats closely resemble Huntington's disease. J. Neurosci. 11: 1649.
2. Beal, M.F., Swartz, K.J., Finn, S.F., Mazurek, M.F. and Kowall, N.W., 1991, Neurochemical characterization of excitotoxin lesions in the cerebral cortex. J. Neurosci. 11:147.
3. Beal., M.F., Kowall, N.K., Swartz, K.J., Ferrante, R.J. and Martin, J.B., 1988, Systemic approaches to modifying quinolinic acid striatal lesions in rats. J. Neurosci. 8:3901.
4. Boegman, R.J., El-Defraqy, S.R., Jhamandas, K., Beninger, R.J. and Ludwin, S.K., 1985, Quinolinic acid neurotoxicity in the nucleus basalis antagonized by kynurenic acid. Neurobiol. Aging, 6:331.
5. Brady, R.J. and Swann, J.W., 1988, Suppression of ictal-like activity by kynurenic acid does not correlate with its efficacy as an NMDA receptor antagonist, Epilepsy Res. 2:232.
6. Burton, N.R., Smith, D.A.S. and Stone, T.W., 1988, A quantitative pharmacological analysis of some excitatory amino acid receptors in mouse neocortex, Brit. J. Pharmacol. 93: 693.
7. Chen, J., Graham, S., Moroni, F. and Simon, R., 1993, A study of the dose dependency of a glycine receptor antagonist in focal ischemia, J. Pharm. exp. Ther, 267:937.
8. Chizhmakov, I.V., Kiskin, N.I., Tsyndrenko, A.Y. and Krishtal, O. A., 1990, Desensitisation of NMDA receptors does not proceed in the absence of kynurenate. Neurosci. Lett. 108:88.
9. Davies, S.W. and Roberts, P.J., 1987, No evidence for preservation of somatostatin-containing neurons after intrastriatal injections of quinolinic acid. Nature, 327:326.
10. Dixon, D.B. and Copenhagen, D.R., 1992, Suppression of a calcium current by CNQX and kynurenate. Neurosci. Lett. 147:147.
11. Figueredocardenas, G., Anderson, K.D.., Chen, Q., Veenman, C.L. and Reiner, A., 1994, Relative survival of striatal projection neurons and interneurones after intrastriatal injection of quinolinic acid in rats. Exp. Neurol. 129:37.
12. Forloni, G.L, Angeretti, N., Rizzi, M. and Vezzani, A., 1992, Chronic infusion of quinolic acid in rat striatum: effects on discrete neuronal populations. J. Neurol. Sci. 108:129.
13. Freese, A., Swartz, K.J., During, M.J. and Martin, J.B., 1990, Kynurenine metabolites of tryptophan: implications for neurologic diseases. Neurology 40:691.
14. Germano, I.M., Pitts, L.H., Meldrum, B.S., Bartkowski, H.M. and Simon, R.P., 1987, Kynurenate inhibition of cell excitation decreases stroke size and deficits. Ann. Neurol. 22: 730.
15. Ghribi, O., Callebert, J., Plotkine, M. and Boulu, R.G., 1994, Effect of kynurenic acid on the ischaemia-induced accumulation of glutamate in rat striatum. Neuroreport 5:435.
16. Henderson, G., Johnson, J.W. and Ascher, P., 1990, Competitive antagonists and partial agonists at the glycine modulatory site of the mouse NMDA receptor., J. Physiol. 430:189.
17. Heyes, M.P., Jordan, E.K., Lee, K., Saito, K., Frank, J.A., Snoy, P. J., Markey, S.P. and Gravell, M., 1992, Relationship of neurologic status in macaques infected with the simian immunodeficiency virus to CSF quinolinic acid and kynurenic acid. Brain Res., 570: 237.
18. Hicks, R.R., Smith, D.H., Gennarelli, T.A. and McIntosh, T., 1994, Kynurenate is neuroprotective following experimental brain injury in the rat, Brain Res. 655:91.
19. 28k immunoreactivity in rat striatal neurons in vivo and in vitro mimic the pattern seen in Huntington's disease. Neurosci. 65: 397.
20. Ignatowicz, E., Vezzani, A.M., Rizzi, M. and D'Incalci, M., 1991, Nerve cell death induced in vivo by kainic acid and quinolinic acid does not involve apoptosis. Neuroreport, 2:651.
21. Jauch, D.A., Sethy, V.H., Weick, B.G., Chase, T.N. and Schwarcz, R. ,1993, Intravenous administration of L-kynurenine to rhesus monkeys: effects on quinolinate and kynurenate levels in serum and CSF. Neuropharmacology 32: 467.
22. Leeson, P.D. and Iversen, L.L., 1994, The glycine site on the NMDA receptor: structure-activity relationships and therapeutic potential. J. Med. Chem., 37:4053.
23. McLarnon, J.G. and Curry, K., 1990, Quinolinate activation of NMDA ion channels in rat hippocampal neurons. Neurosci. Lett. 116:341.
24. Nozaki, K. and Beal, M.F., 1992, Neuroprotective effects of L-kynurenine on hypoxia-ischemia and NMDA lesions in neonatal rats. J. Cereb. Blood Flow Metab., 12:400.
25. Perkins, M.N. and Stone, T.W., 1982, An iontophoretic investigation of the actions of convulsant kynurenines and their interaction with the endogenous excitant quinolinic acid. Brain Res. 247: 184.
26. Popoli, P., Pexxola, A., Domenici, M.R., Sagratella, S., Diana, G., Caporali, M.G., Bronzetti, E., Vega, J. and Scotti de Carolis, A., 1994, Behavioural and electrophysiological correlates of the quinolinic acid rat model of Huntington's disease in rats. Brain Res. Bull., 35:329.
27. Pullan, L.M. and Cler, J.A., 1989, Schild plot analysis of glycine and kynurenic acid at the NMDA excitatory amino acid receptor. Brain Res. 497:59.
28. Reinhard, J.F.jnr., Erickson, J.B. and Flanagan, E.M., 1994, Quinolinic acid in neurological disease: opportunities for novel drug discovery. Adv. Pharmacol. 30:85.
29. Russi, P., Carla, V. and Moroni, F., 1989, Indolepyruvic acid administration increases the brain content of kynurenic acid. Is this a new avenue to modulate excitatory amino acid receptors in vivo? Biochem. Pharmacol. 38: 2405.
30. Stone, T.W., 1993, Neuropharmacology of quinolinic and kynurenic acids, Pharmacol. Revs. 45:309
31. Stone, T.W., 1988, Comparison of kynurenic acid and 2-APV suppression of epileptiform activity in rat hippocampal slices. Neurosci. Lett. 84:234.
32. Stone, T.W., 1991, Kynurenine and glycine enhance neuronal sensitivity to NMDA. Life Sci., 48:765.
33. Stone, T. W. and Burton, N.R., 1988, NMDA receptors and their endogenous ligands in vertebrate CNS. Progr. Neurobiol. 30: 333.
34. Stone, T.W. and Perkins, M.N., 1988, Quinolinic acid: a potent endogenous excitant at amino acid receptors. Europ. J. Pharmacol. 72: 411.
35. Swartz, K.A., During, M.J., Freese., A. and Beal, M.F., 1990, Cerebral synthesis and release of kynurenate : an endogenous antagonist of excitatory amino acid receptors. J. Neurosci. 10: 2965.
36. Williams, T.L., Smith, D.A.S., Burton, N.R. and Stone, T.W., 1988, Amino acid pharmacology in neocortical slices: evidence for bimolecular actions from an extension of the Hill and Gaddum-Schild equations. Brit. J. Pharmacol. 95:805.
37. Wood, E.R., Bussey, T.J. and Phillips, A.G., 1993, A glycine antagonist 7-chlorokynurenic acid attenuates ischemia-induced learning deficits. Neuroreport 4:151.